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Inhibition of lysosomal protease 
cathepsin D reduces renal fibrosis in 
murine chronic kidney disease
Christopher Fox1, Pasquale Cocchiaro1,2, Fiona Oakley1, Rachel Howarth1, 
Krystena Callaghan1, Jack Leslie1, Saimir Luli1, Katrina M. Wood3, Federica Genovese4, 
Neil S. Sheerin1 & Anna Moles1
During chronic kidney disease (CKD) there is a dysregulation of extracellular matrix (ECM) homeostasis 
leading to renal fibrosis. Lysosomal proteases such as cathepsins (Cts) regulate this process in other 
organs, however, their role in CKD is still unknown. Here we describe a novel role for cathepsins in 
CKD. CtsD and B were located in distal and proximal tubular cells respectively in human disease. 
Administration of CtsD (Pepstatin A) but not B inhibitor (Ca074-Me), in two mouse CKD models, 
UUO and chronic ischemia reperfusion injury, led to a reduction in fibrosis. No changes in collagen 
transcription or myofibroblasts numbers were observed. Pepstatin A administration resulted in 
increased extracellular urokinase and collagen degradation. In vitro and in vivo administration of 
chloroquine, an endo/lysosomal inhibitor, mimicked Pepstatin A effect on renal fibrosis. Therefore, 
we propose a mechanism by which CtsD inhibition leads to increased collagenolytic activity due to an 
impairment in lysosomal recycling. This results in increased extracellular activity of enzymes such as 
urokinase, triggering a proteolytic cascade, which culminates in more ECM degradation. Taken together 
these results suggest that inhibition of lysosomal proteases, such as CtsD, could be a new therapeutic 
approach to reduce renal fibrosis and slow progression of CKD.
The worldwide prevalence of chronic kidney disease (CKD) is estimated to be between 8–16% and is predicted to 
rise due to the ageing population and an increase in the incidence of diabetes and hypertension1. There are many 
causes of CKD including ischemic, toxic and infectious insults to the kidney and genetic, endocrine and immu-
nological diseases. Progression of CKD results in end-stage renal disease (ESRD) and organ failure. Treatments 
to stop or slow the progression of CKD to ESRD are currently very limited2, with increasing numbers of patients 
requiring life-long dialysis or transplantation. Glomerulosclerosis and tubulointerstitial fibrosis are two main his-
tological features of CKD. After kidney injury there is a physiological wound healing response to restore normal 
function and tissue homeostasis. However, repetitive insults or dysregulation of this response leads to excessive, 
pathological deposition of extracellular matrix (ECM) proteins such as fibrillar collagens (mainly type I and III), 
fibronectin and laminins. ECM deposition, crosslinking, turnover and degradation are finely regulated in vivo by 
proteases, transglutaminases, lysil oxidases and their inhibitors.
The study of protease biology is challenging at many levels: their regulation is complex occurring during gene 
transcription, cell trafficking, extracellular secretion, activation of latent forms and recycling; their substrate spec-
ificity and preference can vary from in vitro to in vivo and diseased to non-diseased tissues and finally there is a 
high degree of redundancy amongst different proteases, which can lead to complex compensatory mechanisms. 
There are two main families of proteases which have been implicated in the progression of renal fibrosis, metal-
loproteinases (MMP)3 and serine proteases4. However, the role of other proteases such as lysosomal cathepsins 
(Cts) is poorly understood in the context of renal fibrosis, despite playing an important role in other fibrotic 
diseases such as liver (CtsB), lung (CtsK) and heart (CtsL) fibrosis. CtsB inactivation attenuates hepatic damage5 
and reduces scarring6,7 in several experimental models of liver fibrosis. In contrast in bleomycin lung fibrosis 
model, CtsK deficient mice have a worse outcome than wild type mice8, while transgenic overexpressing CtsK 
mice show a reduction in lung fibrosis9. Similarly, CtsL knock-out mice develop spontaneous age-related cardiac 
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fibrosis10 while overexpression of human CtsL in a murine model of cardiac hypertrophy leads to an improvement 
of cardiac function and fibrosis11. Despite the evidence in other organs the role of lysosomal cathepsins in kidney 
fibrosis remains unclear. Therefore the aim of this study was to analyse the role of cathepsins in renal fibrosis. 
Here we describe a novel role for CtsD in kidney fibrosis. Screening of human kidney biopsies showed stronger 
CtsD staining in kidneys with tubular damage, localizing CtsD mainly in cytosolic vesicles of distal tubules. 
Analysis of aspartyl and cysteine cathepsins expression in mouse obstructive nephropathy showed an increase in 
CtsD and B but not L. Pharmacological inhibition of CtsD but not CtsB led to a reduction of kidney fibrosis in two 
different models of CKD, unilateral ureteric obstruction (UUO) and chronic ischemia reperfusion injury (IRI). 
Our in vivo and in vitro observations support a novel mechanism of action by which inhibition of CtsD leads to an 
impairment of lysosomal recycling increasing the amount of active proteases available in the extracellular space, 
such as UPA. Active UPA could then regulate and activate plasmin, enhancing ECM remodelling, ultimately 
reducing renal fibrosis.
Results
CtsD and B are differentially expressed in distal and proximal tubules respectively during 
human kidney disease. We determined the expression of CtsD or CtsB in normal human kidney and a 
range of human kidney diseases: minimal change disease (MCD), IgA nephropathy (IgA N), focal segmental 
glomerulosclerosis (FSGS), diabetic nephropathy (Diabetic N) and anti-neutrophil cytoplasmic antibody 
(ANCA) associated vasculitis (AAV). Analysis by a renal histopathologist identified a common expression 
pattern for all the diseases analysed, with CtsD or CtsB mainly expressed in cytosolic vesicles from distal or 
proximal tubular cells respectively (Fig. 1A). Interestingly, areas with a greater number of damaged tubules 
had more CtsD expression than unaffected areas or normal kidneys. No differences in CtsB expression were 
detected between normal and diseased kidneys (Fig. 1A). Of note, both CtsD and B were also detected in 
some podocytes and glomerular crescents. The distal or proximal tubular distribution of CtsD or B was also 
confirmed by confocal microscopy using thiazide-sensitive NaCl co-transporter (NCC) and aquaporin-1 as a 
distal or proximal tubular markers respectively (Fig. 1B). Based on these observations, CtsD could potentially 
play a role in tubular injury.
Renal CtsD and B expression is induced in obstructive nephropathy. We next analysed aspartyl 
CtsD and cysteine CtsB and L expression in mice kidneys after 7 days Unilateral Ureteric Obstruction (UUO). 
CtsD, L and cysteine cathepsin inhibitors, cystatin B and C, mRNA expression were significantly increased in 
UUO kidneys compared to contralateral unobstructed kidneys, however, CtsB mRNA expression did not change 
(Fig. 2A). Cortical fibrosis in UUO kidneys was confirmed by morphometric analysis of Sirius Red and α -SMA 
(Fig. 2B,C).
Although cathepsins are regulated at the transcriptional level, the main step in regulating their activity occurs 
in the lysosomes where cathepsins are stored as inactive zymogens before being cleaved into the active protease12. 
Pro- and mature CtsD as well as mature CtsB were increased in UUO kidneys. In contrast mature CtsL decreased 
in diseased kidneys (Fig. 2D). To define the time course of CtsD upregulation, protein and mRNA levels were 
measured 5, 7 and 10 days after UUO induction. Both protein and gene expression were significantly upregulated 
by day 5 UUO with further increase by day 7. CtsD mRNA expression rose further by day 10 while protein expres-
sion plateaued after day 7 (Supplementary Fig. S1A,B). Therefore, during UUO there is a differential regulation 
of aspartyl and cysteine cathepsins with an increase of CtsD and B protein expression and processing into mature 
forms and a decrease in mature CtsL.
Pepstatin A reduces kidney fibrosis in two different models of chronic kidney disease. Active 
CtsD and B act as pro-fibrogenic enzymes in liver fibrosis6. To investigate whether the increase in active enzymes 
was playing a role in the development of kidney fibrosis, Pepstatin A (CtsD inhibitor) or Ca074-Me (CtsB inhib-
itor) were administered three times a week for 15 days following UUO. To be more representative of human 
disease, surgery was performed and renal injury was allowed to develop for 5 days before starting treatment, 
by which stage an increase in α -SMA and Col1A1 gene expression was already evident in untreated UUO mice 
(Supplementary Fig. S1C,D). Consistent with Fig. 2D, CtsD activity was significantly increased in injured kid-
neys and reduced back to control levels by Pepstatin A administration. Ca074-Me had no effect on CtsD activity 
assessed by fluorimetric activity in kidney lysates (Fig. 3A). The inhibitory effect of Ca074-Me on CtsB activity 
was demonstrated in vivo in 10 days UUO kidneys by IVIS analysis using a CtsB activable fluorescent probe 
(Fig. 3B). Morphometric analysis of Sirius Red, collagen III and IV cortical staining, showed an increase in fibro-
sis and thickening of the tubular basal membrane in injured kidneys (Fig. 3C–E). Ca074-Me administration 
had no effect over Sirius Red or collagen IV and only a moderate effect over collagen III. However, Pepstatin 
A treatment significantly reduced cortical accumulation of Sirius Red, collagen III and IV in fibrotic kidneys 
(Fig. 3C–E).
The effect of Pepstatin A on kidney fibrosis was confirmed in a second model of chronic ischemia reperfusion 
injury (IRI) (35 minutes of ischemia followed by 28 days of reperfusion). Pepstatin A was again administered from 
5 days post-surgery. CtsD activity was significantly increased in IRI kidneys versus control and Pepstatin A treat-
ment reduced this levels back to normal control as assessed by fluorimetric activity in kidney lysates (Fig. 4A). In 
agreement with the UUO results, Pepstatin A effectively reduced cortical accumulation of Sirius Red, collagen III 
and IV in IRI kidneys (Fig. 4B–D). Thus, CtsD but not B inhibition lead to a reduction in kidney fibrosis in two 
different models of chronic kidney disease.
Pepstatin A reduces kidney fibrosis due to an increase in collagen degradation. The reduction 
in collagen deposition with Pepstatin A treatment could be explained by changes in ECM gene transcription rate, 
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myofibroblasts numbers or ECM degradation rate. Transcript levels of Col1A1, Col3A1 and Col4A1 were signif-
icantly increased in fibrotic kidneys in both models, however, the increase was not affected by Pepstatin A treat-
ment (Fig. 5A–F). Pepstatin A treatment did not affect the cortical area occupied by myofibroblasts, determined 
Figure 1. CtsD and CtsB expression in human normal and diseased kidneys. Representative pictures 
of CtsD or B staining in normal kidney, minimal change disease (MCD), IgA nephrophaty (IgA N), focal 
segmental glomerulosclerosis (FSGS), diabetic nephrophaty (Diabetic N), anti-neutrophil cytoplasmic antibody 
(ANCA) associated vasculitis (AAV) human biopsies (A). A minimum of three different patient biopsies were 
stained per disease. Representative confocal microscopy pictures of NCC/CtsD or Aquaporin-1/CtsB dual 
immunofluorescence of human kidney biopsies (B).
www.nature.com/scientificreports/
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by α -SMA immunostaining, in UUO or IRI kidneys (Fig. 6A,B). Finally, collagenolytic activity was analysed by 
in situ collagen I zymography in UUO cryosections and C3M peptide ELISA13 in sham and IRI serum. In situ 
Figure 2. Aspartyl and cysteine cathepsin expression in 7 day UUO kidneys. CtsD, CtsB, CtsL, Cystatin B 
and Cystatin C mRNA expression (A), morphometric analysis of SR + ve (B) and α -SMA + ve (C) area/field 
and representative pictures of cortex from contralateral and 7 days UUO kidneys. Western Blot of pro and 
mature forms of CtsD, CtsB, CtsL and GAPDH (D) of contralateral and 7 days UUO kidney lysates. N = 7, t-test 
analysis, *P ≤ 0.05 or **P ≤ 0.01.
www.nature.com/scientificreports/
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zymography assesses cleavage of collagen I by using a specific DQTM collagen I fluorescein conjugated substrate. 
When this substrate is intact its signal is quenched by the close proximity of the dyes and only after enzyme-driven 
Figure 3. Cathepsin D inhibition but not B reduces cortical collagen deposition in 15 days UUO model. 
CtsD fluorometric activity in kidney lysates assessed by the cleavage of a specific fluorescently labelled substrate 
(A) IVIS assessed in vivo CtsB kidney activity in 10 days UUO (B). Morphometric analysis and representative 
pictures of Sirius Red (SR) + ve (C), Col3 + ve (D) and Col4 + ve (E) area/field in cortex of contralateral and day 
15 UUO kidneys. Animals were treated with vehicle, Pepstatin A 20 mg/Kg or Ca074-Me 10 mg/Kg from day 5. 
N = 6, 1 way ANOVA,*P ≤ 0.05 or **P ≤ 0.01.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:20101 | DOI: 10.1038/srep20101
Figure 4. Cathepsin D inhibition reduces cortical collagen deposition in a chronic IRI model. CtsD 
fluorometric activity in kidney lysates assessed by the cleavage of a specific fluorescently labelled substrate (A). 
Morphometric analysis and representative images of Sirius Red (SR) + ve (B), Col3 + ve (C) and Col4 + ve (D) 
area/field in cortex of contralateral or IRI kidneys. Ischemia was performed for 35 minutes and kidneys were 
reperfused for 28 days. Animals were treated with vehicle or Pepstatin A 20 mg/Kg from day 5. N = 6, 1 way 
ANOVA, *P ≤ 0.05 or **P ≤ 0.01.
www.nature.com/scientificreports/
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hydrolysis, there is an increase in fluorescence intensity. C3M is a collagen III proteolytic fragment, also called 
neo-peptide, derived from MMP mediated enzymatic cleavage. These peptides can be released from different 
tissues into circulation and are currently under study as possible biomarkers to assess collagen degradation in 
different diseases14. Indeed, C3M has already been reported as a marker for experimental renal fibrosis15. Both 
methods showed higher collagenolytic activities in Pepstatin A treated fibrotic mice (Fig. 6C,D). In summary, 
Pepstatin A effectively reduced fibrosis in two independent models of kidney fibrosis by enhancing collagenolytic 
activity as opposed to changes in the collagen synthesis or myofibroblast numbers.
Pepstatin A activates the urokinase plasminogen activator system. According to our results CtsD 
plays a pro-fibrogenic role in kidney fibrosis, as its inhibition enhances collagen degradation and reduces fibro-
sis. Cathepsins can enhance ECM turnover through activation of other proteases16. The urokinase plasminogen 
activator system plays a role in CKD by directly degrading ECM proteins and activating MMPs17. UPA protein 
expression was induced in fibrotic kidneys compared to the contralateral controls in UUO with a further increase 
after Pepstatin A administration (Fig. 7A). Plasminogen/casein zymography using kidney lysates from the IRI 
model confirmed the UUO results showing an increase in UPA activity in fibrotic kidneys from mice treated with 
Pepstatin A compared to vehicle (Fig. 7B,C).
Urokinase and its receptor (UPAR) are known to be in part regulated through endo/lysosomal recycling once 
UPA has bound its inhibitor PAI17. In vehicle treated fibrotic kidney (UUO and IRI) dual confocal immunofluores-
cence demonstrated co-localization of CtsD and UPA in a vesicle like pattern in the cytosol of tubular cells (Fig. 7D; 
Supplementary Fig. S2). Further confocal analysis of lysosomal-associated membrane protein-2 (LAMP-2), 
as a lysosomal marker, and UPA confirmed the vesicle like pattern as lysosomes (Fig. 7D; Supplementary Fig. S2). 
In summary, in our CKD models Pepstatin A is able to induce an increase in active urokinase. In addition to this, 
CtsD and UPA co-localize in lysosomes in fibrotic kidneys, pointing towards a possible interaction between UPA 
and CtsD within the lysosomes. Our results suggest that affectation of UPA endo/lysosomal recycling by CtsD 
inhibition, could lead to an increase of extracellular UPA, which could then modulate the activation of plasmin 
and potentially MMPs18,19 both of which enhance ECM degradation.
CtsD inhibition enhances UPA secretion by impairing its endo/lysosomal recycling. Our results 
show co-localization of CtsD and UPA in lysosomes (Fig. 7D; Supplementary Fig. S2). UPA/UPAR complex 
Figure 5. Pepstatin A does not affect kidney collagen transcription. Col1A1, Col3A1, Col4A1 mRNA 
expression of kidney cortex from contralateral and 15 days UUO kidneys (A–C) or contralateral and IRI 
kidneys (D–F). UUO was performed for 15 days. Ischemia was performed for 35 minutes and kidneys were 
reperfused for 28 days. Animals were treated with vehicle or Pepstatin A 20 mg/Kg from day 5. N = 6, 1 way 
ANOVA, *P ≤ 0.05 or **P ≤ 0.01.
www.nature.com/scientificreports/
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is known to be recycled through endo/lysosomal internalization17. To investigate whether only CtsD or also 
CtsB has an effect on UPA lysosomal recycling, we treated the human tubular epithelial cell line HKC-8 with 
Pepstatin A and Ca074-Me. As expected only Pepstatin A but not Ca074-Me was able to inhibit CtsD activ-
ity (Supplementary Fig. S3A). UPA WB of concentrated media revealed an increase in extracellular UPA after 
Pepstatin A, but not Ca074-Me treatment (Fig. 8A). Plasminogen/casein zymography confirmed an enhancement 
of UPA activity by Pepstatin A showing three different isoforms of UPA, 55, 40 and 33 KDa20 (Fig. 8B). In agree-
ment, CtsD siRNA transfection also showed an increased in UPA secretion into the extracellular media (Fig. 8C). 
Next we assessed whether Pepstatin A enhanced UPA secretion by affecting its endo/lysosomal recycling through 
Figure 6. CtsD inhibition enhances collagen degradation with no changes in cortical myofibroblast 
numbers. Morphometric analysis of α -SMA + ve area/field of kidney cortex from contralateral and 15 days 
UUO kidneys (A) or contralateral and IRI kidneys (B). Average mean fluorescent intensity and representative 
pictures of DQ collagen I degradation by in situ zymography of day 15 UUO kidneys treated with vehicle or 
Pepstatin A 20 mg/Kg (C). Serum C3M ELISA in sham or IRI mice treated with vehicle or Pepstatin A 20 mg/
Kg (D). UUO was performed for 15 days. Ischemia was performed for 35 minutes and kidneys were reperfused 
for 28 days. Animals were treated with vehicle or Pepstatin A 20 mg/Kg from day 5. N = 6, for A and B, 1 way 
ANOVA, for (C and D), t-test, *P ≤ 0.05 or **P ≤ 0.01.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:20101 | DOI: 10.1038/srep20101
clathrin-mediated endocytosis21. We analysed the UPA cellular distribution in primary human distal tubular epi-
thelial cells (NCC+, cytokeratin-19+, collagen-1−, Supplementary Fig. S3B,C). We demonstrated co-localization 
of AP2-μ 1 adaptor protein, which is essential for the clathrin vesicle formation, with UPA, suggesting that UPA 
was being endocytosed through the clathrin dependent pathway in hDTC (Fig. 8D). In order to impair endo/
Figure 7. UPA expression is enhanced by Pepstatin A in renal fibrosis. UPA and GAPDH western blot 
(A) of contralateral or 15 days UUO kidney lysates. Plasminogen/casein zymography (B) with quantification 
below (C) in contralateral or IRI kidney lysates. Representative dual staining confocal pictures of CtsD/UPA 
or LAMP-2/UPA of a single epithelial tubular cell from a vehicle-treated UUO kidney (D). CtsD or LAMP-2 
(green), UPA (red) and merge with DAPI (blue). Confocal processing was performed by Image J software. 
UUO was performed for 15 days. Ischemia was performed for 35 minutes and kidneys were reperfused for 28 
days. Animals were treated with vehicle or Pepstatin A 20 mg/Kg from day 5. N = 6, repeated measures of t-test, 
*P ≤ 0.05 or **P ≤ 0.01.
www.nature.com/scientificreports/
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lysosomal activity we used the endo/lysosomal inhibitor, chloroquine (CQ). As with Pepstatin A treatment, 
HKC-8 cells treated with CQ showed increased levels of active UPA into the extracellular media by plasminogen/
casein zymography (Fig. 8E). To investigate whether CQ had a similar effect to Pepstatin A in vivo, UUO was 
performed and animals were treated with Pepstatin A, CQ or vehicle. CQ endo/lysosomal inhibition is in part 
due to its ability to prevent endo/lysosomal acidification. This rise in pH will result in reduced lysosomal enzyme 
Figure 8. Pepstatin A enhances UPA secretion in human tubular epithelial cells by impairing its endo/
lysosomal recycling. UPA and GAPDH WB (A) and plasminogen/casein zymography with quantification 
below (B) of concentrated media from HKC-8 cells treated with vehicle, 10μM Ca074-Me or 10μg/mL Pepstatin 
A for 48 hrs. CtsD and β-actin WB in cell lysate and UPA WB in media of hDTC transfected with scramble 
or CtsD siRNA for 48 hrs (C). Representative dual staining confocal pictures of AP2-μ1/UPA in human 
distal tubular epithelial cells (hDTC) (D). Plasminogen/casein zymography with quantification below (E) of 
concentrated media from HKC-8 cells treated with vehicle, 50 μM Chloroquine (CQ), 10μg/mL Pepstatin 
for 48 hrs. Experiments were repeated at least 3 times. Sirius Red (SR)+ve area/field (F) of kidney cortex of 
contralateral and 15 days UUO kidneys treated with vehicle, Pepstatin A 20mg/Kg or Chloroquine 20mg/Kg. 
N=6, repeated measures of t-test, *P ≤ 0.05 or **P ≤ 0.01. 
www.nature.com/scientificreports/
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activity. CtsD activity in UUO kidney lysates from mice treated with CQ showed significantly less CtsD activity 
than vehicle treated UUO kidneys (Supplementary Fig. S3D). Consistent with our in vitro data, CQ was able to 
reduce cortical fibrosis to a similar level as Pepstatin A assessed by Sirius Red staining (Fig. 8F). Taken together 
our results suggest that Pepstatin A enhances UPA secretion by impairing its lysosomal recycling.
Discussion
In this study we clearly demonstrate that inhibition of aspartyl cathepsin D leads to a reduction in interstitial 
fibrosis in two models of renal disease. The number of patients with CKD is increasing and some of these patients 
will progress onto end stage renal disease and face life-long dialysis or organ transplant. Treatment options for 
patients with progressive disease are limited, thus there is an urgent need to find new therapeutic targets that 
could lead to drug development. Interstitial fibrosis is almost invariably seen in patients with progressive CKD. 
Dysregulation of extracellular matrix (ECM) homeostasis leads to a gradual replacement of the healthy nephrons 
by electrondense fibrotic ECM. Proteases play a crucial role in regulating this process; however, our knowledge of 
proteases biology and function in CKD is still very limited.
Lysosomal proteases have been implicated in the pathogenesis of fibrotic disease in the liver, (CtsB and D)6,7 
lung, (CtsK)8,9 and heart, (CtsL)10,11 but very little is known about their function in renal disease. The only reports 
relate to the role of cysteine but not aspartyl cathepsins (CtsD family group). There is decreased activity in the kid-
ney of the cysteine cathepsins B, H and L accompanied by an increase in their urinary secretion in rat polycystic 
kidney disease22, puromycin induced nephrosis23 and rat and human diabetic nephropathy24,25. However, not all 
cysteine cathepsins decrease during proteinuric kidney disease and CtsL26 increases in proximal tubular cells and 
podocytes. Therefore, the role of cathepsins is currently far from understood, pointing towards a cell and disease 
specific function.
Screening of a panel of human renal biopsies show for the first time the expression of CtsD and B in dis-
tal and proximal tubular cells respectively in human renal disease (Fig. 1A,B). In agreement with Goto et al.’s27 
observations in human normal kidney, CtsD is mainly expressed in distal convoluted tubules. Our results point 
towards an increase of CtsD expression in areas of tissue damage with no change in CtsB expression. The number 
of patients screened in our study was insufficient to draw statistical conclusions and further investigations will 
be needed in a bigger cohort to determine an association between level of CtsD expression and disease outcome.
To investigate the role of CtsD and B in CKD we used an aspartyl or cysteine protease inhibitor, Pepstatin A or 
Ca074-Me, in a murine CKD model, UUO. Pepstatin A but not Ca074-Me diminished collagen accumulation and 
thickening of the tubular basement membrane (Fig. 3C–E) with no effect on collagen transcription (Fig. 5A–C) 
or myofibroblast (Fig. 6A) numbers. Pepstatin A effects on fibrosis were reproduced in a second model of CKD, 
35 minutes/28 days IRI (Figs 4B–D,5D,F and 6B). Our results suggest that Pepstatin A reduces fibrosis by increas-
ing collagen I and III degradation (Fig. 6C,D).
Despite Pepstatin A being the best inhibitor against CtsD available and in contrast to Ca074-Me, which is a 
rather specific inhibitor against CtsB28, Pepstatin A can also affect other proteases of the same family, thus addi-
tional effects on other proteases cannot be excluded. Indeed, this may contribute to the outcome of our study, 
as redundancy and compensatory mechanisms12 are common problems when targeting only one member of 
a protease family. CtsD knock-out mice die approximately 26 days after birth due to neurological disorders29 
replicating human deficiency30,31. In our models Pepstatin A did not completely block CtsD activity, achieving a 
reduction back to physiological levels (Figs 3A and 4A), avoiding possible undesirable secondary effects.
Cathepsins can indirectly modulate ECM turnover by affecting other proteases. We investigated the rela-
tionship between CtsD and UPA as an example of how CtsD can affect extracellular protease activity. Urokinase 
(UPA) was upregulated in fibrotic kidneys after the treatment with Pepstatin A (Fig. 7A–C). In vitro, extracellular 
UPA was increased in human tubular epithelial cells treated with CtsD but not B inhibitor and siRNA against 
CtsD (Fig. 8A–C).
UPA belongs to the urokinase plasminogen activator system, the role of which in CKD remains controver-
sial17,32,33. UPA is anti-fibrotic in lung34 and liver35 whereas surprisingly no difference in the severity of UUO 
was observed in UPA knock-out mice36. UPA is secreted extracellularly and activated upon binding to its sur-
face receptor, UPAR. Then activates other proteins, preferentially plasminogen into plasmin, which can directly 
degrade ECM proteins37–39 and also activates MMPs18,19, triggering further ECM degradation. Despite several 
reports in the literature of a direct link between UPA, plasmin and MMP activation, further work is required to 
demonstrate a link to CtsD.
PAI-1, UPA’s natural inhibitor, covalently binds to the UPA:UPAR complex inhibiting UPA’s enzymatic activ-
ity. The UPA:UPAR:PAI-1 complex is then rapidly internalized upon binding to LDL receptor-related protein-1 
(LRP-1) through clathrin dependent endocytosis pathway into the lysosomes21. There UPA and PAI-1 are 
degraded and UPAR is recycled back to the cell surface. We confirmed localization of UPA in clathrin endosomal 
vesicles by co-localizing UPA with AP2-μ 1 adaptor protein, which is an essential protein for the clathrin-coated 
pit formation, in hDTC (Fig. 8D). We also proved co-localization of CtsD and UPA within the lysosomes in 
fibrotic kidneys (Fig. 7D, Supplementary Fig. S2). Previous work by van Kasteren SI et al. support our hypothesis 
of Pepstatin A affecting endo/lysosomal recycling as they described EGFR clathrin dependent endo/lysosomal 
degradation being impaired by a cystatin-pepstatin inhibitor (CPI)40. In order to further confirm a link between 
lysosomal degradation and the increase in UPA, we used chloroquine (CQ) as endo/lysosome inhibitor. Both 
Pepstatin A and CQ had similar effects in vitro, increasing the active extracellular UPA (Fig. 8E). In addition, CQ 
administration in the UUO model mimicked the effect seen with Pepstatin A administration, reducing collagen 
accumulation and fibrosis (Fig. 8F).
In summary, here we report for the first time the distribution of CtsD and B in human renal disease and show 
the effect of their inhibition in two mouse models of renal fibrosis. We propose a novel mechanism by which CtsD 
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inhibition by Pepstatin A leads to an increase in extracellular protease activity, in particular UPA, due to altered 
lysosomal recycling. This can trigger a proteolytic cascade activating first plasminogen into plasmin and culmi-
nating possibly with the regulation and activation of MMPs18,19. Both plasmin37–39 and MMPs are able to degrade 
ECM proteins causing a net reduction in fibrosis. This situation can be further sustained by a positive feedback 
loop, as plasmin is also able to activate UPA20. Our model does not exclude the regulation by CtsD of other pro-
teases that might be recycled through the lysosomal pathway and further investigation will be needed to clarify 
this. This work opens new and exciting prospects for the treatment of CKD by targeting lysosomal proteases.
Methods
Reagents. CtsD fluorimetric activity assay was from Abcam. Pepstatin A, Chloroquine were from Sigma. 
Ca074-Me was from PeptaNova. Cat B 750 FAST Fluorescent Imaging Agent was from Perkin Elmer. DQ™ 
Collagen, type I from Bovine Skin, Fluorescein Conjugate was from Invitrogen Life Technologies. Human 
Plasminogen was from Biopur. Avidin/Biotin blocking kit, Citric acid based antigen unmasking solution, 
Vectastain Elite ABC Reagent, DAB peroxidase substrate kit, Vectashield mounting medium were purchased 
from Vector Laboratories. Unless otherwise reported all other reagents were from Sigma-Aldrich.
Unilateral ureter obstruction (UUO) model of kidney fibrosis. All the animal studies were done in 
accordance to the UK Home Office regulations and under its approval (licence 60/4521). Left proximal ureter 
ligation was performed in 8–10 week C57BL/6 females. Right kidneys were used as controls. Animals were culled 
at 5, 7, 10 and 15 days post-surgery. 15 days UUO mice received intraperitoneal injections of vehicle, Pepstatin A 
(20 mg/Kg), Ca074-Me (10 mg/Kg) or Chloroquine (20 mg/Kg) from day 5 post-surgery three times a week up to 
15 days. A minimum of 6 animals were used in each experimental group.
Chronic ischemia reperfusion (IRI) model of kidney fibrosis. Ischemia was achieved by clamping the 
left renal pedicle for 35 minutes in 8–10 week C57BL/6 females. After 35 minutes the clamp was removed and 
the kidney reperfused for 28 days. Right kidneys were used as controls. Vehicle and Pepstatin A (20 mg/Kg) were 
administered by intraperitoneal injection from day 5 post-surgery three times a week up to 28 days. A minimum 
of 6 animals were used in each experimental group.
Cathepsin B in vivo activity by IVIS imaging. For the IVIS analysis Cathepsin B Prosense 750 probe was 
injected intravenously according to manufacturer´s instructions in 10 days UUO mice. After 7 hours animals 
were anesthetized with isoflurane and scanned using 745 nm excitation and 800 nm emission wavelengths with 
an IVIS Spectrum CT (Caliper Life Sciences). Animals were scanned before injection and the background was 
subtracted. Data was analysed using Living Image 4.2 software, regions of interest (ROI) were drawn and the 
average of the Total Radiant Efficiency [p/s]/[μ W/cm2] was calculated per ROI.
Cell culture. HKC-8 cells41 or NRK-49F (ATCC® CRL 1570™ ) were cultured in 1:1 Dulbecco’s mod-
ified Eagle’s: F12 medium or DMEM supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin, 2 mM 
L-glutamine, 5% FBS, and maintained at 37 °C at an atmosphere of 5% CO2.
siRNA transfection. During treatment cells were cultured in 0% FBS. Cells were transfected with 50 nM 
Scramble or 50 nM CtsD siRNA using INTERFERin (Polyplus) according to manufacturer’s instructions for 
48 hrs. After that, media was collected and cell lysates were performed.
Isolation of human primary distal tubular cells (hDTC). Human kidneys cells were isolated from adult 
kidneys after surgical resection in accordance to the Research Ethics Committee guidelines and approval granted 
by the NRES Committee East Midlands-Derby (REC ref. 13/EM/0311), subject to patient consent. Briefly, after 
removing the kidney capsule, the cortex was mince and digested with 1 mg/ml collagenase IV for 60 minutes at 
37 °C. Digested tissue was passed through a 40 μ m cell strainer and centrifuged at 1200 rpm. Pellet was resus-
pended in RPMI, loaded in a two layer Percoll gradient (50%, 24.6%) and centrifuged at 3000 rpm for 25 minutes 
at 4 °C. Top layer containing DTC was washed twice in RPMI at 1200 rpm. DTC were seeded and maintained in 
DMEM/F-12, GlutaMAX™ supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine, 
10% FBS, and maintained at 37 °C at an atmosphere of 5% CO2. Cells were used in between passage 2 and 3. 
Phenotypic characterisation of the hDTC by WB confirmed they expressed thiazide-sensitive NaCl cotransporter 
(NCC)+ and cytokeratin-19+ but not Collagen 1−. Conversely, the rat kidney fibroblast cell line NRK-49F was 
positive for Collagen 1+ but did not express NCC− or cytokeratin-19− (Supplementary Fig. S3B). Microvilli were 
seen on scanning electron microscopy (Supplementary Fig. S3C). CtsD expression in hDTC was confirmed by 
WB (Supplementary Fig. S3B).
Electron scanning microscopy. hDTC were cultured in 13 mm glass coverslips until full confluence, when 
they were fixed with 2% glutaraldehyde in Sorenson’s Phosphate Buffer overnight at 4 °C. Once fixed, they were 
washed and transferred into 100% ethanol and critically point dried. The cells were then gold coated and scanned 
in a VEGA3 TESCAN microscope.
Immunohistochemistry in mouse and human samples. Immunohistochemistry was performed in 
4 μ m formalin-fixed kidney slides. Sections were deparaffinised and endogenous peroxidase was blocked with 
2% hydrogen peroxide/methanol solution. Antigen retrieval was performed according to Supplementary Table 
S1. Endogenous avidin and biotin were blocked. Blocking solution and primary antibody was added overnight. 
After the addition of the secondary biotinilated antibody and ABC, sections were developed with DAB, coun-
terstain with Mayer’s haematoxylin and mounted. For α -SMA, Collagen III and Collagen IV image analysis was 
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performed at 200X using Nikon Eclipse Upright microscope and NIS-Elements BR Analysis software from Nikon. 
At least 10 random fields of cortex were analysed per kidney. For CtsD and B, human sections were assessed by an 
expert histopathologist (KMW). A minimum of three different patient biopsies were stained per disease.
Study approval for human samples. Access to patient biopsies was approved by the NRES Committee 
East Midlands-Derby Research Ethics Committee (REC ref. 13/EM/0311). Normal, Minimal Change Disease, 
IgA nephropathy, FSGS, Diabetic nephropathy and ANCA associated vasculitis biopsy samples were taken under 
full ethical approval and patient consent, in accordance to the approved guidelines.
Dual immunofluorescence. For sections, 4 μ m formalin-fixed kidney tissue sections were deparaffin-
ised. After microwave citrate saline antigen retrieval, permeabilization with 0.25% Triton X-100 was performed. 
Sections were then blocked with 5% BSA and primary antibodies, Thiazide-Sensitive NaCl Cotransporter (NCC), 
CtsD or LAMP-2 and UPA were applied in 1% BSA overnight. For coverslips, hDTC were cultured in glass cover-
slips, fixed with formalin and permeabilized with 0.1% saponine/0.5% BSA. After blocking with 3% BSA, primary 
antibodies AP2-μ 1 and UPA were applied for 90 minutes. After washing, the secondary antibodies were sequen-
tially added, donkey anti-rabbit Alexa 594 and anti-goat-FITC or goat anti-rat IgG Alexa 488. An extra blocking 
step with 20% rabbit serum was added between secondaries for the CtsD/UPA and the AP2-μ 1/UPA dual stain-
ings. Sections were finally mounted with ProLong® Diamond DAPi conjugated mounting medium (Invitrogen) 
and analysed using a Leica TCS SP2 confocal microscope. Pictures were taken sequentially at 400X or 630X oil. 
1.8 electronic zoom was made of a region of interest. 4 images of 1 μ m slice each were acquired per section or 13 
images of 0.5 μ m slice each were acquired per coverslip. Image analysis was performed using Image J software. A 
detailed list of antibodies is provided in Supplementary Table S2.
Plasminogen/casein zymography. Briefly, whole kidney lysates or concentrated medias mixed with 2× 
Laemmli buffer (Bio-Rad) were resolved in 10% acrylamide/bis-acrylamide gel containing 13 μ g/mL of human 
plasminogen with EACA and 1 mg/mL of β -casein. Gel was washed twice with 2.5% Triton X-100 and incubated 
for 12–33 hrs at 37 °C in 0.1 M glycine soluction at pH: 8.0. The gel was stained with 0.2% Comassie R-250/ 10% 
acetic acid/45% methanol solution for 1 hr and distained with 7% acetic acid/ 40% methanol until optimal band 
resolution.
In situ zymography. Kidney cryostat sections of 6 μ m thickness where coated with low gelling temperature 
agarose containing 0.1 mg/mL DQ™ Collagen, type I fluorescein conjugated and 1 μg/mL of DAPI. Agarose was 
left to set in the fridge for 2 hrs. Then slides were incubated at 30 °C for 20 hrs. Fluorescence was detected using a 
Zeiss AxioImager microscope, 15 random pictures were taken at 200X. Fluorescent intensity was analysed using 
Image J software.
CtsD activity assay. Cathepsin D activity was determined using a fluorescence-based assay 
“Cathepsin D activity assay” from Abcam. This assay utilizes the preferred cathepsin-D substrate sequence 
GKPILFFRLK(Dnp)-D-R-NH2) labelled with MCA. 0.1–10 μ g of protein were used per assay according to man-
ufacturer’s instructions. Assay plates were incubated at 37 °C and readings were performed in a fluorometer at 
355 nm excitation and 520 emission for 2 hours. Results are expressed as a slope of fluorescence emission after 
2 hours per μ g of protein.
Serum C3M Enzyme-linked immunosorbent assay. The specific MMP-generated neo-epitope of the 
collagen type III alpha 1 chain (C3M) was detected by competitive ELISA using a specific monoclonal antibody. 
Assay was performed as previously described13.
Sirius Red staining. Kidneys were fixed with formalin, embedded in paraffin, and sections of 4 μ m were 
routinely stained with 0.1% Sirius Red following standard procedures. Image analysis was performed as described 
in the immunohistochemistry section.
SDS PAGE and immunoblotting. Total kidney or cell lysates were prepared with radioimmune precipi-
tation assay buffer (RIPA). Concentrated medias were prepared using Amicon Ultra-0.5 Centrifugal Filters from 
Millipore. 10–30 μ g of protein were fractionated in 8–12% SDS-PAGE and transferred into nitrocellulose mem-
branes. Blots were incubated with 5% non-fatty dry milk or BSA in 0.1% TBS-Tween. Membranes were incubated 
overnight with primary antibodies, anti-Cathepsin D, anti-UPA, anti-α -SMA, and anti-GAPDH. Membranes 
were washed with TBS-Tween, incubated with secondary HRP conjugated antibodies and develop with ECL 
(Thermo scientific). A detailed list of antibodies is provided in Supplementary Table S2.
RNA Isolation and Real Time PCR. RNA from kidney tissue was extracted with TriReagent. Briefly, RNA 
was precipitated from the aqueous phase with isopropanol and washed with 70% ethanol. Purity was assessed 
using a Nanodrop and cDNA synthesis was performed (Promega RT kit). Real time PCR was performed with 
SYBR Green JumpStart ready mix according to manufacturer’s instructions. Data was calculated using ∆∆Ct and 
18S was used as a housekeeping gene. Data is plotted against vehicle control group. Primer sequences used are 
reported in the Supplementary Table S3.
Statistics. Results are expressed as mean ± SEM unless otherwise stated in the figure legend. All p values were 
calculated using one way ANOVA followed by Bonferroni’s test or two tailed unpaired student’s t-test. *P ≤ 0.05 or 
**P ≤ 0.01 was considered statistically significant.
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Supplementary Figure S1: Cathepsin D expression in UUO time course 
CtsD and GAPDH western blot (A) from kidney lysates. CtsD, α-SMA, Col1A1 
mRNA expression  (B, C, D) from contralateral and 5, 7, 10 days UUO kidneys. 
N=6, t-test, *P ≤ 0.05 or **P ≤ 0.01. 
 
Supplementary Figure S2: Cathepsin D and UPA co-localize within the 
lysosomes in fibrotic IRI kidneys 
Representative dual staining confocal pictures of CtsD/UPA or LAMP-2/UPA of a 
single epithelial tubular cell from fibrotic vehicle IRI kidneys sections. CtsD or 
LAMP-2 (green), UPA (red) and merge with DAPI (blue). Confocal processing 
was performed by Image J software. In this study ischemia was performed for 35 
minutes and kidneys were reperfused for 28 days. Animals were treated with 
vehicle or Pepstatin A 20mg/Kg from day 5. N=6, 1 way ANOVA, *P ≤ 0.05 or **P 
≤ 0.01. 
 
Supplementary Figure S3: Pepstatin A enhances UPA secretion by human 
tubular epithelial  
CtsD fluorometric activity assay in HKC-8 cell lysates (A) from HKC-8 cells 
treated with vehicle, 10μM Ca074-Me or 10μg/mL Pepstatin A for 48 hrs. Anti-
Thiazide-Sensitive NaCl Cotransporter (NCC), Cytokeratin-19, Collagen type 1, 
CtsD and β-actin Western Blot in hDTC lysates from 4 different preparations at 
passage 2 and NRK-49F rat fibroblast cell line (RKF) lysates (B). Representative 
electron microscopy images of hDTC at passage 3 (C). Pictures were taken at 
500X and 5000X. CtsD fluorometric activity in kidney lysates of 15 days UUO 
vehicle and chloroquine treated mice assessed by the cleavage of a specific 
fluorescently labelled substrate (D). Experiments were repeated at least 3 times. 
t-test, *P ≤ 0.05 or **P ≤ 0.01.   
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Supplementary table 1: Detailed instructions for immunohistochemistry staining 
Antigen retrieval Primary antibody 
20μg/mL 
Proteinase K 
Rabbit polyclonal Collagen IV  
(ab19808, Abcam)  
20μg/mL 
Proteinase K 
Goat anti-collagen III 
(1330-01, Southern Biotech) 
Sodium citrate antigen 
unmasking solution 
Monoclonal Anti-Actin, α-Smooth  
Muscle (F3777, Sigma- Aldrich) 
Sodium citrate antigen 
unmasking solution 
Rabbit polyclonal anti-Cathepsin D   
(sc10725, St Cruz Biotechnology) 
Sodium citrate antigen 
unmasking solution 
Rabbit polyclonal anti-Cathepsin B 
(NBP1-19797, Novus Biologicals) 
 
 
Supplementary table 2: Primary antibody list 
Dual immunofluorescence WB 
AP-2µ1 (sc-49150, St Cruz) α-SMA (A5228, Sigma) 
Aquaporin-1 (sc-9878, St Cruz) β-actin (A5316, Sigma) 
CtsB (sc-13985, St Cruz) CtsB (sc-13985, St Cruz) 
CtsD (sc-6486, St Cruz) CtsD (sc-6486, St Cruz) 
LAMP-2 (ab13524, Abcam) CtsL (ab133641, Abcam) 
Anti-Thiazide-Sensitive NaCl 
Cotransporter or NCC (AB3553, Merck 
Millipore) 
GAPDH (ab22555, Abcam) 
UPA (sc-14019, St Cruz) UPA (sc-14019, St Cruz) 
 





Gene (GenBank Accession) Primer sequence 
α-SMA  (NM_007392) 
Fw: 5’-TCAGCGCCTCCAGTTCCT-3’ 
Rv: 5’-AAAAAAAACCACGTAACAAATCAA-3’ 
Col1A1  (NM_007742) 
Fw: 5’-TTCACCTACAGCACGCTTGTG-3’ 
Rv: 5’-GATGACTGTCTTGCCCCAAGTT-3’ 
Col 3A1 (NM_009930) 
Fw: 5’-CTGTAACATGGAAACTGGGGAAA-3’ 
Rv: 5’-CCATAGCTGAACTGAAAACCACC-3’ 
Col 4A1 (NM_009931) 
Fw: 5’-TCCGGGAGAGATTGGTTTCC-3’ 
Rv: 5’-CTGGCCTATAAGCCCTGGT-3’ 
CtsB  (NM_007798) 
Fw: 5’-TCCTTGATCCTTCTTTCTTGCC-3’ 
Rv: 5’-ACAGTGCCACACAGCTTCTTC-3’ 






Cystatin B (NM_007793) 
Fw: 5’-AGGTGAAGTCCCAGCTTGAAT-3’ 
Rv: 5’- GTCTGATAGGAAGACAGGGTCA-3’ 
Cystatin C  (NM_009976) 
Fw: 5’-AGGAGGCAGATGCCAATGAG-3’ 
Rv: 5’-GGGCTGGTCATGGAAAGGA-3’ 
